Volume 84, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We aimed to evaluate the effectiveness of nitazoxanide in disseminated cystic echinococcosis (DCE) that failed to respond to surgical and antiparasitic therapy. We report on seven patients (five of them with bony involvement): two cases from the literature and five patients who were included in a compassionate trial of nitazoxanide therapy in our hospital. Median follow-up time until nitazoxanide therapy was 12 years and all patients had received prior medical treatment and extensive surgery. Nitazoxanide (500 mg/12 h) in combination with albendazole, with/without praziquantel, was administered for 3–24 months. Three patients improved: one with muscle involvement (clinico-radiological response), one with lung involvement (radiological response), and another with soft tissue and bony involvement (clinico-radiological response of soft tissue cysts). There was one discontinuation after 15 days of starting therapy. Nitazoxanide combination therapy could have a role in the treatment of DCE when there is no bony involvement. Long-term safety profile seems to be favorable.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization and World Organization for Animal Health Eckert J, Gemmell M, Meslin F, Pawłowski Z, , 2001. WHO/OIE Manual on Echinococcosis in Humans and Animals: a Public Health Problem of Global Concern. , eds.
  2. Schantz P, Kern P, Brunetti E, Guerrant R, Walker D, Weller P, , 2006. Echinococcosis. , eds. Tropical Infectious Diseases: Principles, Pathogens and Practice. Philadelphia, PA: Elsevier, Churchill Livingstone, 13041326.
  3. Brunetti E, Junghanss T, , 2009. Update on cystic hydatid disease. Curr Opin Infect Dis 22: 497502.[Crossref]
  4. Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E, , 2008. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 79: 301311.
  5. World Health Organization, 2001. PAIR: Puncture, Aspiration, Injection, Re-Aspiration. An option for the treatment of Cystic Echinococcosis. WHO/CDS/CSR/APH/2001.6.
  6. Dervenis C, Delis S, Avgerinos C, Madariaga J, Milicevic M, , 2005. Changing concepts in the management of liver hydatid disease. J Gastrointest Surg 9: 869877.[Crossref]
  7. Falagas ME, Bliziotis IA, , 2007. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci 334: 171179.[Crossref]
  8. Bygott JM, Chiodini PL, , 2009. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop 111: 95101.[Crossref]
  9. Jamshidi M, Mohraz M, Zangeneh M, Jamshidi A, , 2008. The effect of combination therapy with albendazole and praziquantel on hydatid cyst treatment. Parasitol Res 103: 195199.[Crossref]
  10. Horton J, , 2003. Albendazole for the treatment of echinococcosis. Fundam Clin Pharmacol 17: 205212.[Crossref]
  11. Stojkovic M, Zwahlen M, Teggi A, Vutova K, Cretu CM, Virdone R, Nicolaidou P, Cobanoglu N, Junghanss T, , 2009. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 3: e524.[Crossref]
  12. Dziri C, Haouet K, Fingerhut A, Zaouche A, , 2009. Management of cystic echinococcosis complications and dissemination: where is the evidence? World J Surg 33: 12661273.[Crossref]
  13. Favennec L, Jave Ortiz J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF, , 2003. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 17: 265270.[Crossref]
  14. Rossignol JF, Ayoub A, Ayers MS, , 2001. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184: 381384.[Crossref]
  15. Rossignol JF, Ayoub A, Ayers MS, , 2001. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 184: 103106.[Crossref]
  16. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB, , 2008. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 28: 574580.[Crossref]
  17. Gilles HM, Hoffman PS, , 2002. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol 18: 9597.[Crossref]
  18. Rossignol JF, Maisonneuve H, , 1984. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 33: 511512.
  19. Walker M, Rossignol JF, Torgerson P, Hemphill A, , 2004. In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes. J Antimicrob Chemother 54: 609616.[Crossref]
  20. Gavidia CM, Gonzalez AE, Lopera L, Jayashi C, Angelats R, Barron EA, Ninaquispe B, Villarreal L, Garcia HH, Verastegui MR, Gilman RH, , 2009. Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep. Am J Trop Med Hyg 80: 367372.
  21. Stettler M, Rossignol JF, Fink R, Walker M, Gottstein B, Merli M, Theurillat R, Thormann W, Dricot E, Segers R, Hemphill A, , 2004. Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity. Int J Parasitol 34: 615624.[Crossref]
  22. Stettler M, Fink R, Walker M, Gottstein B, Geary TG, Rossignol JF, Hemphill A, , 2003. In vitro parasiticidal effect of nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 47: 467474.[Crossref]
  23. Reuter S, Manfras B, Merkle M, Harter G, Kern P, , 2006. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 50: 29662970.[Crossref]
  24. Schipper HG, Simsek S, van Agtmael MA, van Lienden KP, , 2009. Bone hydatid disease refractory to nitazoxanide treatment. Am J Trop Med Hyg 81: 446448.
  25. Winning A, Braslins P, McCarthy JS, , 2009. Case report: nitazoxanide for treatment of refractory bony hydatid disease. Am J Trop Med Hyg 80: 176178.
  26. WHO Informal Working Group, 2003. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop 85: 253261.[Crossref]
  27. Prabhakar MM, Acharya AJ, Modi DR, Jadav B, , 2005. Spinal hydatid disease: a case series. J Spinal Cord Med 28: 426431.[Crossref]
  28. Sengul G, Kadioglu HH, Kayaoglu CR, Aktas S, Akar A, Aydin IH, , 2008. Treatment of spinal hydatid disease: a single center experience. J Clin Neurosci 15: 507510.[Crossref]
  29. Tuncer E, Tas SG, Mataraci I, Tuncer A, Donmez AA, Aksut M, Yakut C, , 2010. Surgical treatment of cardiac hydatid disease in 13 patients. Tex Heart Inst J 37: 189193.
  30. Loudiye H, Aktaou S, Hassikou H, El-Bardouni A, El-Manouar M, Fizazi M, Tazi A, Hajjaj-Hassouni N, , 2003. Hydatid disease of bone. Review of 11 cases. Joint Bone Spine 70: 352355.[Crossref]
  31. Horton RJ, , 1997. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 64: 7993.[Crossref]
  32. El-On J, , 2003. Benzimidazole treatment of cystic echinococcosis. Acta Trop 85: 243252.[Crossref]
  33. Franchi C, Di Vico B, Teggi A, , 1999. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. Clin Infect Dis 29: 304309.[Crossref]
  34. Homeida M, Leahy W, Copeland S, Ali MM, Harron DW, , 1994. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol 88: 551559.[Crossref]
  35. Yasawy MI, Alkarawi MA, Mohammed AR, , 2001. Prospects in medical management of Echinococcus granulosus . Hepatogastroenterology 48: 14671470.
  36. Anderson VR, Curran MP, , 2007. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67: 19471967.[Crossref]
  37. 2007. Alinia. Summary of product characteristics. Tampa, FL: Romark Pharmaceuticals. Available at: www.romark.com.
  38. Hemphill A, Mueller J, Esposito M, , 2006. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 7: 953964.[Crossref]
  39. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB, , 2009. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136: 856862.[Crossref]

Data & Media loading...

  • Received : 12 Sep 2010
  • Accepted : 18 Nov 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error